SCHEMBL16260503

SCHEMBL16260503

Cc1ccc(N2CC[C@@H](F)C2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.49
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48
PDE10A Q9Y233 1/20 0.47
HRH3 Q9Y5N1 1/20 0.44
SLC6A9 P48067 3/20 0.44
DRD2 P14416 3/20 0.42
DRD1 P21728 3/20 0.42
DRD5 P21918 3/20 0.42
DRD3 P35462 3/20 0.42
HTR1A P08908 1/20 0.42
DRD4 P21917 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034211 1.00 GPR119 (0.49) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL16260556 1.00 GPR119 (0.49) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14734000 0.90 GPR119 (0.55) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1351672 0.85 GPR119 (0.48) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1351675 0.85 GPR119 (0.48) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17696406 0.84 MAP4K4 (0.50) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL18752408 0.83 GPR119 (0.49) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13724794 0.83 GPR119 (0.49) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL18752394 0.83 GPR119 (0.49) GPR119GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21664701 0.83 GPR119 (0.46) GPR119GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305778-B1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2022-01-19 EP disclosed
EP-3305778-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2018-04-11 EP disclosed
EP-2999697-B1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LTD (GB) 2017-04-19 EP disclosed
US-20160108036-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-04-21 US disclosed
WO-2014188211-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2014-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108036-A1 HETEROCYCLIC DERIVATES BDKRB1, KLKB1, BDKRB2 GPR119 586/4885GRIN2D 3873/4885GRIN3B 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.